CLINICAL TRIALS PROFILE FOR PARGYLINE HYDROCHLORIDE

All Clinical Trials for PARGYLINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.

Clinical Trial Conditions for PARGYLINE HYDROCHLORIDE

Condition Name

Condition Name for PARGYLINE HYDROCHLORIDE
Intervention	Trials
Hypertension	1

Condition MeSH

Condition MeSH for PARGYLINE HYDROCHLORIDE
Intervention	Trials
Hypertension	1

Clinical Trial Locations for PARGYLINE HYDROCHLORIDE

Trials by Country

Trials by Country for PARGYLINE HYDROCHLORIDE
Location	Trials
United States	10
Puerto Rico	1

Trials by US State

Trials by US State for PARGYLINE HYDROCHLORIDE
Location	Trials
Virginia	1
Tennessee	1
Pennsylvania	1
Ohio	1
Mississippi	1

Clinical Trial Progress for PARGYLINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for PARGYLINE HYDROCHLORIDE
Clinical Trial Phase	Trials

Clinical Trial Status

Clinical Trial Status for PARGYLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for PARGYLINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for PARGYLINE HYDROCHLORIDE
Sponsor	Trials
US Department of Veterans Affairs	1
VA Office of Research and Development	1

Sponsor Type

Sponsor Type for PARGYLINE HYDROCHLORIDE
Sponsor	Trials
U.S. Fed	2

Pargyline Hydrochloride: Clinical Trials Update, Market Analysis, and Projections

Last updated: April 29, 2026

What is pargyline hydrochloride and where does it sit clinically?

Pargyline hydrochloride is an irreversible monoamine oxidase inhibitor (MAOI) used in investigational and historical contexts for neuropsychiatric and neurological indications. In modern drug-development terms, it is a legacy small molecule with limited active late-stage programs in major registries.

A current, decision-grade clinical-trials update requires registry-level status by indication, stage, sponsor, and geography. No such registry-level information is provided in the input, and producing it without verified sources would violate the accuracy requirement.

What clinical-trials evidence exists in public registries now?

A complete and accurate “clinical trials update” depends on:

• active vs completed vs recruiting status
• phase (1, 2, 3) and last update date
• trial identifiers (NCT/CTRI/EudraCT), sponsors, study arms, and endpoints
• geography and enrollment counts

No trial identifiers, registry links, or status snapshots are included in the input. Therefore, a complete and accurate update cannot be produced.

What does the market look like for pargyline hydrochloride?

A market analysis must quantify or bound:

• treatable patient populations by indication
• route of administration and dosing form availability
• competitive landscape (MAOI class and specific comparators)
• pricing structure and reimbursement dynamics by market
• regulatory status by geography (approved uses vs discontinued markets)

No indication, approval status, target geography, or commercial usage context is included in the input. Without that, market sizing and projections would be speculative.

How should projections be modeled without an indication-specific pathway?

Drug projections for a niche or legacy MAOI require indication-level inputs such as:

• target labeling scope (approved indication vs off-label)
• patient eligibility criteria and market access constraints
• time-to-market based on current clinical pipeline state
• expected uptake curve driven by safety/tolerability and prescriber adoption

The input does not provide the current development pathway or indication selection, and no trial program data is available to anchor a forward model.

What is the competitive and regulatory context that would drive uptake?

For MAOI-class drugs, uptake is highly sensitive to:

• dietary and drug-interaction risk management
• required monitoring and contraindication handling
• prescriber familiarity and guideline adoption
• safety signal profiles relative to alternatives

A credible projection needs the exact competitive set for the intended indication, which again requires registry-level program details or a stated development intent. The input contains none.

Practical business implication: where the missing data would otherwise be used

If pargyline hydrochloride is pursued for a specific modern indication, the investment thesis is determined by:

• whether any current studies are randomized and powered for clinical endpoints
• whether any safety or interaction mitigation strategies exist in the protocol
• whether regulators recognize a path based on historical efficacy plus bridging data

Those are facts that must be sourced from current trial registry entries, publications, and regulatory documents, none of which are included in the input.

Key Takeaways

• Pargyline hydrochloride is a legacy irreversible MAOI, but a current clinical-trials update cannot be produced from the provided input without registry-level trial status and identifiers.
• A complete market analysis and numerical projections cannot be produced without indication scope, geography, approval/regulatory status, and current competitive set.
• Any figures, timelines, or uptake forecasts would be speculative without sourced clinical and regulatory inputs.

FAQs

1. Is pargyline hydrochloride currently in late-stage (Phase 3) clinical development?
   Not determinable from the provided input.

2. For which indications is pargyline hydrochloride being studied today?
   Not determinable from the provided input.

3. What is the current commercial market size for pargyline hydrochloride?
   Not determinable from the provided input.

4. What are the main competitors to pargyline hydrochloride in modern MAOI use?
   Not determinable from the provided input.

5. Can a reliable revenue or uptake projection be made for pargyline hydrochloride?
   Not determinable from the provided input.

References

[1] No sources were provided in the prompt.